Amyotrophic lateral sclerosis is one of the most challenging diagnoses in neurology. It moves fast, it speaks loudly, and it leaves patients, families, and clinicians searching for traction in an area where traction has historically been difficult to find.

Cerebral palsy affects approximately 17 million people worldwide, making it the most common cause of physical disability in childhood. Yet for most families and clinicians, management tends to center on symptom control — physiotherapy, antispasticity medications, surgical procedures — with relatively little attention to the biological signals that drive individual variation in outcomes.

Living with Charcot-Marie-Tooth disease means navigating a condition that most clinicians see only a handful of times in their careers. The classic advice — physical therapy, orthotics, watch for falls — is not wrong, but it stops well short of what current science now makes possible.

Living with Friedreich's ataxia — or supporting someone who does — means navigating a condition where the body's most fundamental energy machinery is under attack. It is not simply about coordination or balance.

Gaucher disease sits in an unusual place in medicine: rare enough that many physicians see only a handful of cases throughout their careers, yet consequential enough that a missed or delayed diagnosis can mean years of unexplained fatigue, bone crises, and progressive organ enlargement.

Living with hereditary spastic paraplegia, or watching a family member navigate its progression, brings a particular kind of uncertainty. The condition moves slowly enough that it can feel manageable one year, then noticeably different the next.

Inclusion body myositis has a way of being misread for years. The grip that quietly loosens, the stairs that become a calculation, the swallowing that starts to require concentration — these are not vague symptoms, but they belong to a disease that remains underdiagnosed, often confused with polymyositis or simply with aging.

Living with Isaac's syndrome means navigating something most physicians rarely see and most patients never fully understand. The persistent muscle stiffness, cramping, twitching, and exhaustion are real, measurable, and often debilitating — yet the conversation too often ends with a rare-disease label, a prescription for a membrane stabilizer, and a vague optimism that symptoms might settle.

If you are reading this, you have probably already heard the word mannosidosis in a room that felt too quiet, or you found MAN2B1 or MANBA sitting inside a genetic report and started searching before you finished reading the rest of the page.

Nemaline myopathy is one of those diagnoses that arrives with a clinical label but very little practical guidance attached to it. You or someone you care for may know by now that the condition involves abnormal protein aggregates — nemaline rods — accumulating inside muscle fibers, disrupting the architecture that makes contraction possible.

Niemann-Pick disease is not a single condition. It is a group of inherited lysosomal storage disorders defined by a molecular failure in how the body processes specific fats — primarily sphingomyelin and cholesterol — at the cellular level.

Living with Parkinson's disease — or supporting someone who does — brings a particular kind of uncertainty that most clinical visits do not fully address. The tremors, the rigidity, the gradual erosion of movement confidence: these are real, and they are frustrating.